Table 3.

Response rates in subset of patients with measureable disease (per RECIST) at baseline

Analysis Group	Outcome	All Patients	EGFR FISH-Positive	EGFR FISH Non-Positive
All Patients	Cetuximab Arm RR, 95% CI	257/617 = 42% (38% – 46%)	87/187 = 47% (39% – 54%)	170/430 = 40% (35% – 44%)
	Control Arm RR, 95% CI	227/623 = 36% (33% – 40%)	82/191 = 43% (36% – 50%)	145/432 = 34% (29% – 38%)
	p-value	0.06	0.48	0.07
Bevacizumab	Cetuximab Arm RR, 95% CI	126/266 = 47% (41% – 53%)	44/83 = 53% (42% – 64%)	82/183 = 45% (38% – 52%)
	Control Arm RR, 95% CI	118/255 = 46% (40% – 52%)	46/75 = 61% (50% – 72%)	72/180 = 40% (33% – 47%)
	p-value	0.80	0.29	0.35
No Bevacizumab	Cetuximab Arm RR, 95% CI	131/351 = 37% (32% – 42%)	43/104 = 41% (32% – 51%)	88/247 = 36% (30% – 42%)
	Control Arm RR, 95% CI	109/368 = 30% (25% – 34%)	36/116 = 31% (23% – 39%)	73/252 = 29% (23% – 35%)
	p-value	0.03	0.11	0.11
Squamous Cell Histology	Cetuximab Arm RR, 95% CI	59/150 = 39% (32% – 47%)	23/50 = 46% (32% – 60%)	36/100 = 36% (27% – 45%)
	Control Arm RR, 95% CI	54/155 = 35% (27% – 42%)	21/54 = 39% (26% – 52%)	33/101 = 33% (24% – 42%)
	p-value	0.42	0.46	0.62
Non-Squamous Histology	Cetuximab Arm RR, 95% CI	198/467 = 42% (38% – 47%)	64/137 = 47% (38% – 55%)	134/330 = 41% (35% – 46%)
	Control Arm RR, 95% CI	173/468 = 37% (33% – 41%)	61/137 = 45% (36% – 53%)	112/331 = 34% (29% – 39%)
	p-value	0.09	0.72	0.07

Footnote: RR = Response rate; CI = Confidence Interval